Kong J
National Vaccine and Serum Institute, Beijing.
Zhonghua Liu Xing Bing Xue Za Zhi. 1993 Jun;14(3):151-4.
Hep-2 cell-based microtiter assay system was used to test the titer of TOPV(Sabin strain). Before immunization, the overall potency results of TOPV produced by China, Yugoslavia, and Belgium were 6.38, 6.25, and 5.75 log TCID 50/0.1 ml, respectively. After storage at 37 degrees C for 2 days or after 5 cycles of freezing and thawing, the overall titer of each TOPV reduced less than 0.5 log TCID 50/0.1 ml. A randomized study was conducted in Anhui Province to test the serological difference among the TOPV which were produced by China, Yugoslavia and Belgium. The formulations of the TOPV produced by China and Yugoslavia were 6.0, 5.0, and 5.5 log TCID 50/0.1 ml of Sabin types 1, 2, and 3, respectively. All of the children in this study were divided into three groups, and children in group A, B, and C received TOPV produced by China, Yugoslavia, and Belgium, respectively. Three doses of TOPV were given to the children in the group at 2, 3, and 4 months of age. The seroconversion rates and geometric mean titers had no significant differences among these groups before immunization. At the end of one month following the 2nd dose, the rates of seroconversion to type 1-3 poliovirus in group A, B, and C were 88%, 98%, 98%; 92%, 98%, 92%; 100%, 100% and 96%, respectively. The rate of seroconversion to type 1 poliovirus in group C was higher than those in group A and B.(ABSTRACT TRUNCATED AT 250 WORDS)
采用基于Hep-2细胞的微量滴定分析系统检测口服脊髓灰质炎减毒活疫苗（TOPV，萨宾株）的滴度。免疫前，中国、南斯拉夫和比利时生产的TOPV总体效力结果分别为6.38、6.25和5.75 log TCID50/0.1 ml。在37℃保存2天或经过5次冻融循环后，各TOPV的总体滴度降低均小于0.5 log TCID50/0.1 ml。在安徽省进行了一项随机研究，以检测中国、南斯拉夫和比利时生产的TOPV之间的血清学差异。中国和南斯拉夫生产的TOPV中，萨宾1型、2型和3型的配方分别为6.0、5.0和5.5 log TCID50/0.1 ml。本研究中的所有儿童分为三组，A组、B组和C组儿童分别接种中国、南斯拉夫和比利时生产的TOPV。在儿童2、3和4月龄时给该组儿童接种三剂TOPV。免疫前，这些组之间的血清转化率和几何平均滴度无显著差异。在第2剂接种后1个月结束时，A组、B组和C组对1-3型脊髓灰质炎病毒的血清转化率分别为88%、98%、98%；92%、98%、92%；100%、100%和96%。C组对1型脊髓灰质炎病毒的血清转化率高于A组和B组。（摘要截断于250字）
